Corvus Pharmaceuticals (NASDAQ: CRVS)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Corvus Pharmaceuticals (NASDAQ: CRVS) through any online brokerage.
Other companies in Corvus Pharmaceuticals’s space includes: Cabaletta Bio (NASDAQ:CABA), Acurx Pharmaceuticals (NASDAQ:ACXP), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD) and GlycoMimetics (NASDAQ:GLYC).
The latest price target for Corvus Pharmaceuticals (NASDAQ: CRVS) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting CRVS to rise to within 12 months (a possible 288.35% upside). 50 analyst firms have reported ratings in the last year.
The stock price for Corvus Pharmaceuticals (NASDAQ: CRVS) is $1.03 last updated August 12, 2022, 8:00 PM UTC.
The next Corvus Pharmaceuticals (CRVS) dividend date is projected to be Thursday, September 1, 2022.
Corvus Pharmaceuticals’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Corvus Pharmaceuticals.
Corvus Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.